Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference26 articles.
1. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes;Bassand;Eur Heart J,2007
2. Ticagrelor: the first reversibly binding oral P2Y receptor antagonist;Husted;Cardiovasc Ther,2009
3. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin;Husted;Eur Heart J,2006
4. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial;Cannon;J Am Coll Cardiol,2007
5. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes;Storey;J Am Coll Cardiol,2007
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Model‐Informed Dosing Regimen of Ticagrelor in Chinese Patients With Acute Coronary Syndrome;Clinical Pharmacology & Therapeutics;2023-10-02
2. Pharmacokinetics, bioequivalence and safety of two formulations of ticagrelor in healthy Chinese subjects: Effects of food;Basic & Clinical Pharmacology & Toxicology;2023-01-25
3. Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis;Alimentary Pharmacology & Therapeutics;2022-11-14
4. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel;Clinical and Translational Science;2022-05-18
5. Hepatic Interactions in Atherosclerotic Heart Disease;The American Journal of the Medical Sciences;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3